The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin,
pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the …

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it
relies on second-line drugs that are less potent and more toxic than those used in the …

Background New antituberculosis regimens are urgently needed to shorten tuberculosis
treatment. Following on from favourable assessment in a 2 week study, we investigated a …

Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics,
pharmacodynamics, clinical efficacy, safety, dosage, and administration of bedaquiline, a …

Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …

ON DECEMBER 31, 2012, THE US FOOD AND DRUG Administration (FDA) announced its
approval of a new drug to treat multidrug-resistant tuberculosis (MDR-TB). The agency …

Introduction: Outcomes of treatment for resistant tuberculosis are poor, with long treatment
duration and poor tolerability. Bedaquiline is a novel anti-mycobacterial drug, which has a …

Background The emergence of drug resistance is a major threat to global tuberculosis (TB)
care and control. The World Health Organization (WHO) estimates that up to half a million …

Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for
treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the …

Treatment of multidrug-resistant tuberculosis (MDR-TB) is hindered by limited efficacy and
significant toxicity of second-line drugs. The need for new therapeutic options is critical to …